Source: GlobalNewswire

Press Release: ProMIS Neurosciences : ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.

Read full article »
Annual Revenue
$100-500M
Employees
1-25
Neil K. Warma's photo - Interim-CEO of ProMIS Neurosciences

Interim-CEO

Neil K. Warma

CEO Approval Rating

82/100

Read more